Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) - Share price


Stock Report

Alnylam Pharmaceuticals Inc ALNY

Last Price
$148.75

Day Change
0.65|0.44%

As of 01/03/2021
17:35:28 EST | USD
Minimum 15 Minutes Delay.

Last Close148.10
Day Range147.95 - 151.35
Mkt Cap17.40Bil
52-Wk Range84.97 - 178.41
Yield %-
ISINUS02043Q1076
Volume443,294
P/E-
P/S34.72
P/CF-27.81

Share Price

Financials
201820192020
More ...
Income Statement
Revenue74.91219.75492.85
Operating Income-814.67-939.43-828.44
Net Income-761.50-886.12-858.28
Basic EPS-7.57-8.11-7.46
Avg. Diluted Shares Outstanding101109115
Balance Sheet
Current Assets1,200.701,715.862,114.78
Non Current Assets374.11679.271,292.28
Total Assets1,574.802,395.133,407.06
Current Liabilities179.49352.59585.27
Total Liabilities272.84956.442,390.81
Total Equity1,301.971,438.691,016.25
Cash Flow
Operating Cash Flow-562.62-278.43-614.96
Capital Expenditure-126.89-140.16-70.36
Free Cash Flow-689.50-418.58-685.32

In millions, except "Basic EPS". Currency is USD.

Company Profile

Alnylam Pharmaceuticals Inc is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Mid-Growth

Fiscal Year Ends

December

Employees

1,453
Key Stats
More ...
Price/Earning TTM-19.85
Price/Book17.05
Price/Sales TTM42.05
Rev Growth (3 year avg)76.32
EPS Growth (3 year avg)-
Operating Margin % TTM-168.09
Net Margin % TTM-174.15
ROE TTM-69.92
Debt/Equity0.48
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.